Track your comments!
[x]


When you register, comments on your articles and replies to your comments appear here. Register Now!

Sign in to your account
[x]

Not a Scientific Blogging member yet?

Register Now for a Free Scientificblogging.com Account

  • Customize your profile with pictures, banner, a blogroll and more.
  • Leave comments on articles, add other members to your friend lists, chat with people on the site.
  • Write blog posts that can be seen by hundreds of thousands of readers.

It's free and it only takes a minute!

Already a Scientific Blogging member?

Sign In Now

Banner
By Anna Ohlden | July 28th 2008 04:33 AM | Print | E-mail | Track Comments

HONG KONG, July 28 /PRNewswire/ --

- Company Receives CE Mark Approval for Non-Compliant Balloon That Provides Controlled Strength and Superb Deliverability

OrbusNeich today announced the addition of the Sapphire NC coronary dilatation catheter to its product line-up with the receipt of CE Mark approval.

A non-compliant balloon, Sapphire NC has controlled growth of only 0.6% per atmosphere of pressure over the working pressure range for controlled dilatations. Furthermore, it has a high 22 atmospheres rated burst pressure for confident treatment of tough, calcified lesions and for post-stent dilatation.

"Sapphire NC is a reliable, easily deliverable, high performance balloon with assured results when used during percutaneous coronary intervention," said Huay-Cheem Tan, M.D., of National University Hospital in Singapore.

Sapphire NC combines advanced precision and material engineering technologies to provide optimum reliability and deliverability. The balloon catheter's HIST (HIgh Speed Tracking) tip enables flexible tracking along the guidewire, while OrbusNeich's TIFO (Tight Fold) processing results in a slender profile for enhanced crossability through tight lesions. Sapphire NC is available in a wide range of sizes for precise dilatation to match popular stent lengths.

OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. The company's product portfolio includes the Genous(TM) Bio-engineered R stent(TM), an antibody-coated device that is the first-ever stent to capture a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process following placement. Other products are stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent(TM), Scoreflex(TM), Sapphire(TM), Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.

As a global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; Tokyo; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.

Editor's Note: Product graphics available on request

Web site: http://www.OrbusNeich.com

Global Media, David Schull of Russo Partners LLC, +1-212-845-4271 (office), or +1-858-717-2310 (mobile), david.schull@russopartnersllc.com